Abstract

Guillain-Barré syndrome (GBS) is an inflammatory polyneuropathy characterized by acute onset, rapid progression, symmetric muscular weakness, pain, and paresthesias. The incidence of GBS in the pediatric age group is 0.8 cases per 100,000; 50%-70% of the cases are preceded by respiratory or gastrointestinal infectious episodes or vaccination. The etiopathogenesis of GBS has been hypothesized to involve a direct immune-mediated mechanism against the peripheral nerves. A series of 20 patients managed in the Department of Pediatrics of the University of Catania between 2003 and 2011 and evaluated according to epidemiologic, clinical, and therapeutic features is reported.

Authors

Pavone P, Praticò AD, Ruggieri M, Verrotti A, Castellano-Chiodo D, Greco F, Falsaperla R, Pavone L

Source

International journal of immunopathology and pharmacology 25:2 pg 513-7

MeSH

Adolescent
Anti-Retroviral Agents
Autoantibodies
Biological Markers
Child
Child, Preschool
Disability Evaluation
Drug Therapy, Combination
Female
Gangliosides
Guillain-Barre Syndrome
Humans
Immunoglobulins, Intravenous
Italy
Male
Neurologic Examination
Predictive Value of Tests
Recurrence
Retrospective Studies
Severity of Illness Index
Steroids
Time Factors
Treatment Outcome

Pub Type(s)

Letter

Language

eng

PubMed ID

22697084